D.E. Shaw & Co
SGMT icon

D.E. Shaw & Co’s Sagimet Biosciences SGMT Stock Holding History

D.E. Shaw & Co’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.15M Sell
411,570
-73,926
-15% -$412K ﹤0.01% 2857
2025
Q4 		$2.87M Sell
485,496
-215,745
-31% -$1.55M ﹤0.01% 2756
2025
Q3 		$4.81M Buy
701,241
+557,393
+387% +$4.52M ﹤0.01% 2239
2025
Q2 		$1.1M Buy
+143,848
New +$607K ﹤0.01% 3173

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

D.E. Shaw & Co's SGMT Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Sagimet Biosciences (SGMT) stake by 15% in Q1 2026, selling an estimated $412K and leaving 411,570 shares worth $2.15M. The position accounts for ﹤0.01% of the portfolio, ranked #2857.

D.E. Shaw & Co first reported a position in SGMT in Q2 2025 and has held it in 4 quarters since. The position peaked at $4.81M in Q3 2025. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • D.E. Shaw & Co held 411,570 shares of Sagimet Biosciences worth $2.15M as of Q1 2026.
  • D.E. Shaw & Co sold 73,926 Sagimet Biosciences shares in Q1 2026, an estimated $412K.
  • Sagimet Biosciences made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #2857 holding.
  • D.E. Shaw & Co first reported a position in Sagimet Biosciences in Q2 2025 and has held it in 4 quarters since.
  • D.E. Shaw & Co's Sagimet Biosciences position peaked at $4.81M in Q3 2025.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.